Citius Pharmaceuticals Inc (CTXR)

[traderdogzz]

Citius Pharmaceuticals Inc. (CTXR) Licenses Mino-Wrap From MD Anderson Cancer Center


- New technology designed to reduce infections after implantation of devices

- First target is breast tissue expanders

- Intended for minimizing serious complications of post-operative infections associated with implants

- Expands relationship with the world's top rated cancer center

CRANFORD, N.J., Jan. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that a definitive license agreement has been reached with MD Anderson Cancer Center ("MDACC") to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. The initial product called "Mino-Wrap", or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
https://finance.yahoo.com/news/citius-licenses-mino-wrap-md-140000769.html